Adrienne Waks, MD

Articles

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

January 27th 2023

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

Managing HER2+ Breast Cancer With Leptomeningeal Metastases

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

January 27th 2023

Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.

Agents in Development for HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

January 20th 2023

Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.

Optimizing Care of Patients on T-DXd for HER2+ mBC With CNS Disease

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

January 20th 2023

Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.

HER2+ Metastatic Breast Cancer: Guidance on MRI Use After CNS Radiation

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

January 13th 2023

A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.

Patient Case 3: HER2+ Metastatic Breast Cancer With CNS Disease

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

January 13th 2023

Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.

Novel Combination Strategies in HER2+ Metastatic Breast Cancer With CNS Disease

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

January 6th 2023

Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.

HER2+ mBC With CNS Disease: Sequencing Therapy After Progression on Tucatinib

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

January 6th 2023

Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.

HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

December 30th 2022

A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.

HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

December 30th 2022

Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.

Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease

Sarah M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

December 23rd 2022

Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.

Patient Case 2: HER2+ Breast Cancer With CNS Metastases

Sarah M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

December 23rd 2022

Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.

Strategies to Identify and Delay Brain Metastases in HER2+ Breast Cancer

Sarah M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

December 16th 2022

A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.

HER2+ Metastatic Breast Cancer: Factors in Selecting Optimal Therapy

Sarah M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

December 16th 2022

Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.

Treatment Armamentarium for HER2+ Metastatic Breast Cancer

Sarah M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS

December 9th 2022

Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.

Patient Case 1: Patient With HER2+ Metastatic Breast Cancer and no CNS Disease

Sarah M. Tolaney, MD, MPH;Nancy U. Lin, MD;Ayal A. Aizer, MD, MHS;Sarah Sammons, MD;Adrienne Waks, MD

December 9th 2022

Expert panelists open their discussion on HER2+ breast cancer by reviewing a patient case of metastatic disease with no CNS involvement.